14 October 2025
Incanthera plc
("Incanthera" the "Company")
Notice of Annual General Meeting 2025 and Posting of Annual Report and Accounts
Incanthera plc (AQSE: INC), the company focused on innovative technologies in dermatology and oncology, confirms that the Annual Report and Accounts for the year ended 31 March 2025, and the Notice of Annual General Meeting ("AGM") with accompanying Form of Proxy has been posted to shareholders and to the Company's website today.
These documents are available, in electronic form, for download on the Company's website: www.incanthera.com
Incanthera's AGM will be held at 11:00 am on Friday 7 November 2025 at the offices of Gateley Plc, 1 Paternoster Square, London EC4M 7DX.
In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible.
Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 6 November 2025, 09:00 BST, or submitted at any time during the AGM itself.
Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link:
https://www.investormeetcompany.com/incanthera-plc/register-investor
Investors who already follow Incanthera plc on the Investor Meet Company platform will automatically be invited.
The Board will respond to key questions during the meeting and will provide such answers on its website thereafter.
For further information please contact:
| Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications
|
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
| Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes
|
+44 (0) 20 7213 0880 |
| Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.
Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.
The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.
Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.
Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.